13 (13) News
Follow 13 (13) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
HUTCHMED Closes License Deal With GSK Outside China
HUTCHMED says customary closing conditions have been completed for its license of a KRAS-EGFR-antibody conjugate therapy to GSK outside China.
MNA | Oct 21, 2026, 12:04 AM UTC
L
Major drugmakers turn to China for licensing deals
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-
GEOPOLITICS | Sep 30, 2026, 12:18 PM UTC
L
Hutchmed (China) Says Astrazeneca Submits US NDA For Orpathys Plus Tagrisso
HUTCHMED (China) Ltd HKEX:13
GEOPOLITICS | Sep 29, 2026, 01:50 AM UTC
L
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination
HUTCHMED (China) HKEX:13 said on Tuesday that Anglo-Swedish drugmaker AstraZeneca LSE:AZN had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination to treat patients with advanc
GEOPOLITICS | Sep 29, 2026, 12:42 AM UTC
L
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination
HUTCHMED (China) HKEX:13 said on Tuesday Anglo-Swedish drugmaker AstraZeneca LSE:AZN had filed an application with the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO combination in patients with ad
GEOPOLITICS | Sep 29, 2026, 12:17 AM UTC
L
HUTCHMED (China) Limited Files US NDA for ORPATHYS Plus TAGRISSO in MET-Driven EGFRm NSCLC
HUTCHMED said AstraZeneca submitted a US FDA NDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET overexpression/amplification EGFR-mutated NSCLC after progression on an EGFR-TKI, supported by positive Phase
GEOPOLITICS | Sep 29, 2026, 12:08 AM UTC
L
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy —— Application supported by SAFFRON,
NEWS | Sep 29, 2026, 12:08 AM UTC
L
Weekly Recap: Phase III savolitinib+osimertinib results and HMPL-A830 deal
Hutchmed China Limited (US) (NASDAQ:HCM) will unveil Phase III data at ESMO 2026 showing savolitinib+osimertinib improved PFS and OS in EGFR—mutant NSCLC with MET alterations, while HCM struck an exclusive global (ex—Chi
GEOPOLITICS | Sep 28, 2026, 11:05 AM UTC
L
Hutchmed (China) Initiates Global Phase A Trial Of HMPL-A830 In Advanced Solid Tumors
HUTCHMED (China) Ltd HKEX:13
GEOPOLITICS | Sep 28, 2026, 01:35 AM UTC
L
HUTCHMED (China) Limited Starts Phase I Trial of KRAS-EGFR ATTC HMPL-A830
HUTCHMED initiated the Phase Ia part of a global first-in-human trial of KRAS-EGFR ATTC HMPL-A830 in advanced solid tumors, with first dosing on Sept. 24, 2026 in China. A GSK subsidiary holds rights ex-Mainland China, H
GEOPOLITICS | Sep 28, 2026, 12:01 AM UTC
L
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
First-in-class KRAS-payload leveraging synchronized EGFR inhibitionHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 27, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM;
GEOPOLITICS | Sep 28, 2026, 12:01 AM UTC
L
HUTCHMED (China) Limited To Present Positive Phase III NSCLC Data at ESMO
HUTCHMED said two positive Phase III studies of savolitinib plus osimertinib in EGFR-mutated NSCLC will be presented at ESMO 2026, including SAFFRON in the Presidential Symposium and SANOVO in a Proffered Paper session.M
GEOPOLITICS | Sep 24, 2026, 12:02 AM UTC
H
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compou
GEOPOLITICS | Sep 24, 2026, 12:02 AM UTC
L
Citi says Hutchmed-GSK deal validates platform pre-clinical
Citi analysts say Hutchmed’s licensing deal with GSK appears to validate the company’s drug candidate platform ahead of clinical trials. The deal could be worth up to US$1.295 billion, excluding additional components.
GEOPOLITICS | Sep 04, 2026, 06:07 AM UTC
L
Citi Research raises Hutchmed target price to HK$39.00
Citi Research raised its target price on Hutchmed (China) to HK$39.00 from HK$36.00.
GEOPOLITICS | Sep 04, 2026, 06:02 AM UTC
M
HUTCHMED and GSK announce $1.3B deal for KRAS-EGFR antibody conjugate
HUTCHMED announced a licensing and co-development deal with GSK for a novel KRAS-EGFR antibody conjugate. The agreement includes $1.3 billion in potential value, with HUTCHMED leading phase I trials and GSK taking over e
GEOPOLITICS | Sep 03, 2026, 12:31 PM UTC
M
Hutchmed signs $1.3B GSK licensing deal for KRAS-EGFR therapy
Hutchmed announced a licensing and co-development agreement with GSK for HMPL-A830, a novel KRAS-EGFR antibody conjugate, valued at $1.3 billion with milestone and royalty potential. Deal aims to accelerate global develo
GEOPOLITICS | Sep 03, 2026, 12:04 PM UTC
M
HUTCHMED China licenses HMPL-A830 to GSK in up-to $1.295B deal
HUTCHMED (China) has entered a global licensing agreement with GSK for HMPL-A830, aiming to accelerate development and validate its ATTC platform. Deal terms include up to $1.295 billion in potential payments plus tiered
GEOPOLITICS | Sep 03, 2026, 10:02 AM UTC
M
GSK secures ex-Greater China rights to KRAS-EGFR therapy; $110M upfront
GSK won global licensing rights excluding Greater China to develop and commercialize a KRAS-EGFR antibody-targeted cancer therapy. Deal includes $110 million upfront plus up to $1.185 billion in milestones, with initial
GEOPOLITICS | Sep 03, 2026, 07:02 AM UTC
M
Hutchmed licenses KRAS-EGFR antibody-conjugate therapy from GSK
Hutchmed (China) Limited announced an exclusive licensing agreement with GSK covering the KRAS-EGFR antibody conjugate cancer therapy, including HMPL-A830.
GEOPOLITICS | Sep 03, 2026, 06:00 AM UTC
M
Hutchmed signs exclusive development and license deal with GSK
Hutchmed (China) said it entered an exclusive development and license agreement with GSK for a cancer drug, including a $110 million upfront payment and milestone payments for development, regulatory and commercial goals
GEOPOLITICS | Sep 03, 2026, 05:21 AM UTC
L
Hutchmed announces licensing agreement with GSK for cancer therapy
HUTCHMED (China) Ltd (HKEX:13) said it has announced a licensing agreement with GSK for a Kras-EGFR-antibody conjugate cancer therapy.
GEOPOLITICS | Sep 03, 2026, 04:23 AM UTC
L
AstraZeneca and Hutchmed combo shows promise in advanced lung cancer
TradingView News says an AstraZeneca-Hutchmed drug combination showed promise in an advanced lung cancer study.
EQUITY | Sep 01, 2026, 06:47 AM UTC
L
Hutchmed China SANOVO trial shows significant PFS benefit
Hutchmed China Ltd says its SANOVO trial demonstrated significant PFS benefit.
GEOPOLITICS | Sep 01, 2026, 06:01 AM UTC
M
HUTCHMED SANOVO trial shows progression-free survival benefit for ORPATHYS plus TAGRISSO
HUTCHMED says its SANOVO trial demonstrated a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
GEOPOLITICS | Aug 31, 2026, 12:07 AM UTC
M
Hutchmed China gets conditional NMPA approval for ATLED in China
Hutchmed (China) announced NMPA conditional approval for ATLED in China.
GEOPOLITICS | Aug 28, 2026, 06:21 AM UTC
M
Hutchmed China gets NMPA approval for ATLED in ICC
Hutchmed China Ltd received NMPA approval for ATLED (fanregratinib) for ICC.
GEOPOLITICS | Aug 28, 2026, 06:00 AM UTC
M
Hutchmed (China) gets NMPA conditional approval for Atled in China
Hutchmed (China) announced NMPA conditional approval for Atled (fantegratinib) in China.
GEOPOLITICS | Aug 28, 2026, 12:38 AM UTC
M
Hutchmed gets NMPA approval for ATLED in FGFR2+ intrahepatic cholangiocarcinoma
HUTCHMED announced NMPA approval for ATLED (fanregratinib) for patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
EQUITY | Aug 28, 2026, 12:07 AM UTC